INTRODUCTION {#S5}
============

Necrotizing enterocolitis (NEC) is a form of intestinal inflammatory disease that develops in 5--12% of premature infants with a mortality of 20--35% ([@R1],[@R2]). Infants with NEC present initially with abdominal distension, feeding intolerance, and bloody stools but often progress to systemic disease with multi-organ involvement and shock ([@R2],[@R3]). It is generally accepted that risk factors, which portend intestinal mucosal injury or aberrant intestinal such as prematurity, hyperosmolar feeds, ischemia, formula milk feeding, and antibiotics are associated with NEC ([@R1]--[@R3]). However, the presence of these risk factors is neither necessary nor sufficient for NEC occurrence or severity in preterm infants. Recent studies have therefore attempted to determine genetic factors that contribute to the variation in liability to NEC observed in the presence of known risk factors ([@R4],[@R5]). A major focus of investigation has been the immune system, as animal data and human studies indicate that aberrant activation of innate immune responses contributes to inflammation and mucosal injury in NEC ([@R1],[@R6],[@R7]). In this multi-center study, we investigated the relationship between sequence variants in the Nucleotide Oligomerization Domain (NOD)-Like Receptor (NLRs) genes and NEC in premature infants.

NLRs are a family of evolutionary conserved intracellular immune receptors that recognize pathogen associated molecular patterns (PAMPs) and danger associated molecular patterns (DAMPs) in immune and non-immune cells ([@R8]--[@R10]). They play important roles in regulating immunity, apoptosis and autophagy, and their function/dysfunction has been extensively studied in the context of gastrointestinal tract homeostasis and inflammatory bowel disease ([@R8]--[@R10]). NOD1 and NOD2 recognize bacterial moieties produced during the synthesis or degradation of the bacterial cell wall component, peptidoglycan. NOD1 senses D-glutamyl-meso-diaminopimelic acid (DAP) primarily from Gram-negative bacteria, while NOD2 senses muramyl dipeptide (MDP), present ubiquitously in Gram-positive and Gram-negative bacteria. NOD1 and NOD2-dependent bacterial recognition activates pro-inflammatory signaling through the NF-κB and MAPK pathways ([@R9],[@R10]). Additionally, NOD1 and NOD2 signaling primes bacterial autophagy, a process by which bacteria are marked for autophagolysosomal clearance by recruiting the key autophagy protein Autophagy related 16-Like 1 (ATG16L1) ([@R10],[@R11]). In contrast with NOD1 and NOD2, other members of the NLR family, such as NLRP3, regulate inflammasome function ([@R11],[@R12]). The NLRP3 inflammasome is a multimeric protein complex that assembles in the cytoplasm upon sensing PAMPs and non-microbial stimuli such as uric acid, ATP, and reactive oxygen species ([@R11],[@R13]). Activation of the NLRP3 complex initiates pro-Caspase-1 (apoptotic factor) and pro-IL-1β processing with subsequent release of active proteins. The Caspase Recruitment Domain containing protein-8 (CARD8) interacts with NLRP3 and NOD2 to inhibit inflammation ([@R12],[@R14]).

Genetic variants in NLRs modulate susceptibility to inflammatory bowel disease (IBD), Crohn's disease, and immunodeficiency in humans ([@R12],[@R13],[@R15]--[@R18]). Specifically, loss or gain of function variants in NOD1 (rs6958571), NOD2 (rs2066844), ATG16L1 (rs2241880), CARD8 (rs2043211), and NLRP3 (rs4353135, rs6672995, and rs35829419) have been associated with altering susceptibility or severity of IBD in adults and children ([@R13]--[@R15], [@R20], [@R21]). Given the general acceptance of: 1) dysregulated innate immune responses in NEC, 2) the wide array of bacterial PAMPs and DAMPs in the premature infant gut that can be sensed by NLRs, and 3) the known association of NLR genetic variants with IBD, a disease characterized by dysregulated intestinal immune responses, we hypothesized that functional genetic variants in NLR pathway genes will be associated with NEC in premature infants. In this study, we tested this hypothesis in a large cohort of premature infants.

RESULTS {#S6}
=======

Epidemiology of NEC in our primary cohort {#S7}
-----------------------------------------

We recruited one thousand and fifteen (n=1015) premature infants with a gestational age (GA) ≤ 35 weeks from multiple centers for our primary cohort. Eighty six infants (8.5%) were diagnosed with NEC in our primary cohort. Birthweight, antenatal steroid use, proportion of males, type of feeding, rates of medically-treated PDA and clinical chorioamnionitis were not significantly different among infants with or without NEC ([Table 1](#T1){ref-type="table"}). NEC rates decreased with advancing GA (p=0.006). Data on clinical chorioamnionitis and type of feeding were not available for 385 infants. We noticed a non-significant trend towards increased NEC among infants of African American descent \[23/197 (11.7%) vs. 63/818 (7.7%), p=0.07\], and among infants with a birth weight \<1000g (p=0.07).

NLR variants and NEC in the primary cohort {#S8}
------------------------------------------

Hardy-Weinberg equilibrium was confirmed at the seven loci investigated. Genotype frequencies of NLR variants among infants without NEC, all NEC, and surgical NEC are shown in [Table 2](#T2){ref-type="table"}. Genotyping data were not obtained in 9 subjects for one or more variants because of inadequate sample. Using an additive risk model we found no association between the NOD1 (rs6958571), NLRP3 (rs4353135, rs6672995, rs35829419), NOD2 (rs2066844), and CARD8 (rs2043211) SNPs and NEC in our cohort ([Table 2](#T2){ref-type="table"}). The ATG16L1 (rs2241880, Thr300Ala) variant was associated with NEC (p=0.009, Cochran-Armitage trend test) in our cohort. NEC (All NEC) prevalence was highest among infants with the AA genotype and decreased proportionately with addition of the G allele ([Figure 1a](#F1){ref-type="fig"}). The AA, AG and GG genotype frequencies of the ATG16L1 SNP did not vary with gestational age at birth in the overall cohort (median; 27wk vs. 28wk vs. 27wk, p=0.70), or in infants with NEC. Compared to infants with the GG genotype, infants with the AA genotype had a 2.5-fold increase in NEC (OR=2.5, 95% CI = 1.2--5.6, p=0.01). In logistic regression models for NEC that included clinical variables and SNPs only gestational age (OR = 0.9; 95%CI = 0.83--0.99, p=0.033) and the ATG16L1 variant (GG vs. AA, OR = 0.4; 95%CI = 0.19--0.81, p=0.036) were associated with NEC. The Hosmer and Lemeshow Goodness-of-Fit test statistic was p=0.32.

ATG16L1 variant in a replication cohort {#S9}
---------------------------------------

To replicate the association between NEC and the ATG16L1 variant discovered in the primary cohort we genotyped this variant in an independent replication cohort of 260 premature infants. There were 23 infants with NEC (8.9%) in this replication cohort. Similar to our primary cohort, we found that NEC rates were highest among infants with the AA (12.5%) genotype and lowest among infants with the GG (6.6%) genotype ([Figure 1b](#F1){ref-type="fig"}). However, this association was not statistically significant.

ATG16L1 variant and NEC outcomes by race {#S10}
----------------------------------------

Because our study cohort was genetically heterogeneous, and genotype frequencies of the ATG16L1 (rs2241880, Thr300Ala) variant differ in African American (AA) and Caucasian (CAU) populations, we examined the relationship between the ATG16L1 SNP and NEC among CAU and AA infants separately. In our primary cohort (n=1015), there were 710 CAU infants, 57 (8%) of whom developed NEC. Presence of the A allele was associated with a significant increase (p=0.02) in NEC rates. Among the 197 AA infants in our primary cohort 23 infants (11.7%) developed NEC. There was a non-significant trend (p=0.10) towards increased NEC among infants with the A allele. To investigate the association between the ATG16L1 variant and NEC in CAU and AA infants in our entire cohort we pooled data from the primary and replication cohorts. The allele frequency (MAF) of the G allele was 49% (859/1752) and 34% (191/562) in CAU and AA infants, respectively ([Figure 2](#F2){ref-type="fig"}). NEC was diagnosed in 71/876 (8.1%) CAU infants and 32/281 (11.4%) AA premature infants. The association between the A allele of the ATG16L1 variant and increased NEC was statistically significant in CAU infants (p=0.01, Cochran Armitage trend) and showed a non-significant trend (p=0.07) in AA infants ([Figure 2](#F2){ref-type="fig"}).

ATG16L1 and surgical NEC {#S11}
------------------------

To examine the relationship between the ATG16L1 variant and disease severity we used surgical NEC as a marker. In our primary cohort, surgical NEC was diagnosed in 26 infants. In six infants with NEC (n=86) we did not have information on surgical NEC. There was a statistically non-significant trend towards increased surgical NEC with the A allele \[AA vs. AG vs. GG; 11/319 (3.5%) vs. 12/475 (2.5%) vs. 3/207 (1.4%)\] ([Table 2](#T2){ref-type="table"}). We found an association between presence of the A allele of the NOD1 (rs6958571) variant and increased NEC (CA trend test; p=0.042). In regression models that corrected for confounding variables, only GA was associated with surgical NEC (Odds ratio -- 0.78; 95%CI − 0.65--0.91, p=0.001).

DISCUSSION {#S12}
==========

While it is increasingly accepted that genetic factors play a role in NEC pathogenesis, robust susceptibility loci for NEC have not been identified ([@R1],[@R21]). Given the importance of the NLR pathway in regulating intestinal immune responses and altering susceptibility to IBD, we postulated that dysregulated NLR signaling will contribute to NEC in premature infants. To test this hypothesis, we took a genetic approach by determining whether common (minor allele frequency (MAF) \>1%), function-altering NLR genetic variants modulate NEC risk in premature infants. The major finding of this study is that a loss of function ATG16lL1 variant (rs2241880, Thr300Ala) was associated with decreased NEC in our primary cohort, and among infants of self-declared Caucasian ancestry. Candidate variants in the NOD1, NOD2, CARD8, and NLRP3 genes were not associated with NEC. Although this study provides preliminary evidence of a role for autophagy in human NEC, lack of correlation with functional data in the preterm intestine and the selective nature of our genotyping approach are limitations of this study.

The ATG16L1 variant (rs2241880, Thr300Ala) has not been investigated with respect to NEC. We found that presence of the A allele at the ATG16L1 locus (g.28152A\>G) was associated with increased NEC in our primary cohort. Disease risk increased additively {NEC risk; AA (11%) \>AG (7.8%) \>GG (3.9%)} with presence of the A allele. The association between the ATG16L1 variant and NEC remained significant after correcting for potential confounders by logistic regression. The mean allele frequency of the G allele among CAU (0.49) and AA (0.34) infants in our study is comparable to the mean allele frequency of the G allele reported in the ExAC browser (<http://exac.broadinstitute.org>) and published studies ([@R20],[@R22]). Similarly, allele frequencies of other variants examined in this study are similar to those reported in prior studies ([@R12],[@R15],[@R23],[@R24]). To decrease the possibility of false association arising from analyzing heterogeneous populations we performed race-segregated analysis. The A allele of the ATG16L1 variant was associated with increased NEC in CAU infants, and showed a trend towards increased NEC in AA infants. Interestingly, AA infants who are known to be at higher risk of NEC have a lower frequency of the protective G allele of the ATG16L1 SNP. Although we were not able to replicate our findings in an independent cohort, NEC rates were highest among infants with the AA genotype in the replication cohort. We speculate that the lack of replication is most likely due to a limited sample size of the replication cohort. Similarly, we did not find an association between the ATG16L1 variant and surgical NEC. Possible explanations for these findings are that the variant increases susceptibility to NEC but not severity, center differences in the practice of surgical interventions, presence of other genetic or clinical confounders, and inadequate power to delineate an effect on surgical NEC.

ATG16L1 variants have been extensively studied in Crohn's disease, a disease characterized by dysregulated NLR responses to gut bacteria ([@R20],[@R22]). Presence of the variant G allele at the ATG16L1 locus (g.28152A\>G) locus confers additive risk of Crohn's disease in adults and children ([@R20],[@R22]). These results are in contrast with our data that suggest increased risk with the A allele. Potential explanations to explain this discrepancy include developmental state of the immune system in infants vs. adults, and pathophysiological differences between NEC and Crohn's disease ([@R1],[@R25]). NEC develops in the context of immature innate immunity, while Crohn's disease occurs in the setting of mature intestinal immunity. NEC is postulated to be a phenotype for exaggerated TLR signaling while the pathophysiology of Crohn's disease involves aberrant NOD-dependent signaling and imbalances in autophagic and adaptive immune responses ([@R1],[@R4],[@R25]--[@R27]). Further, while the microbiome has been implicated in the pathogenesis of both NEC and Crohn's disease, it evolves dynamically with postnatal maturity in the premature infant ([@R28],[@R29]). Intestinal dysbiosis characterized by decreased species diversity, relative abundance of pathogenic bacteria, and an acute increase in *Proteobacteria spp* at the expense of *Firmicutes spp* has been described in infants who develop NEC ([@R1],[@R28],[@R29]). These studies indicate that intestinal dysbiosis creates a pro-inflammatory milieu in premature infants that can evolve into NEC in susceptible individuals ([@R1],[@R4],[@R6]). We speculate that the hypomorphic G allele of ATG16L1 variant may decrease gut dysbiosis-related inflammation, thereby conferring NEC protection. Another key variable that can modulate the gut microbiome, gene-biome interactions and timing of NEC onset is the use of antibiotics in premature infants ([@R1],[@R4],[@R28],[@R29]). We did not have adequate data on postnatal age of NEC onset and duration and timing of antibiotic exposure to evaluate the relationships with the ATG16L1 risk allele. Whether autophagy contributes to intestinal adaptation and bacterial immunity in the preterm infant, and whether defective autophagy contributes to NEC pathogenesis remain key questions that need to be investigated.

The mechanism by which the ATG16L1 variant programs aberrant autophagy and inflammation have recently come to light ([@R17],[@R30]). ATG16L1 forms a multimeric complex with ATG12 and ATG5, which facilitates elongation and completion of the autophagosome ([@R11],[@R31]). NOD1 and NOD2-bacterial sensing recruits ATG16L1 to the plasma membrane with subsequent formation of the autophagosome wrapping bacterial invaders ([@R11],[@R31]). The A\>G SNP on exon 9 encodes a Thr300 to Ala variant that enhances caspase-mediated protein degradation resulting in decreased function ([@R17],[@R32]). In Crohn's disease, defects in ATG16L1-mediated clearance of bacteria arising from the variant G allele elicits chronic mucosal inflammation and injury ([@R30],[@R32]). In contrast, our data indicating less NEC among infants with the variant G allele suggests that decreased autophagic signaling in the developing intestine may be protective. Similar to our results, lack of ATG16L1 has been shown to be protective in the context of intestinal bacterial resistance and carcinoma ([@R16],[@R33]). Marchiando et al. ([@R16]) showed that ATG16L1−/− mice have a hyperimmune response and less mortality compared to wild-type controls during Citrobacter *spp*. enteral infections, suggesting that ATG16L1 deficiency confers protection against selective bacteria. In humans with colonic cancer, presence of the variant G allele was associated with increased type I interferon expression, and improved survival ([@R33]). These data suggest that decreased autophagy resulting from ATG16L1 variant allele may confer protection against NEC. Studies in animal models suggesting a role for autophagy in propagating NEC support our data demonstrating less NEC with a loss of function autophagy variant ([@R34],[@R35]). Access to intestinal tissue from infants with and without NEC would have enabled us to study alterations in intestinal immune and autophagic signaling in relation with the ATG16L1 variant. Investigating whether transgenic mice expressing the mutant allele are more vulnerable to NEC in experimental models ([@R7],[@R27],[@R32]) would help clarify the role of ATG16L1 in NEC.

Because NOD1 and NOD2 regulate immune responses to gut bacteria in neonates we examined candidate variants and NEC outcomes ([@R8],[@R18]). The loss of function NOD2 SNP (rs2066844, Arg702Trp) is associated with Crohn's disease, while the gain of function NOD1 variant (rs6958571), a marker for an indel polymorphism (NOD1+32656), has been variably associated with early-onset IBD ([@R8],[@R15],[@R19],[@R36]--[@R38]). The NOD variants were not associated with NEC in our cohort. This is consistent with a prior small study in premature infants showing no association between NOD variants and NEC ([@R39]). Similarly, a recent study did not find any association between the NOD2 SNP (rs2066844) and NEC, although presence of two of more NOD2 SNPs was associated with NEC ([@R24]). We speculate that while genetically-mediated dysregulated NOD signaling plays a role in chronic inflammation characteristic of IBD, it may not contribute to acute inflammation observed in NEC. Two NLRP3 SNPs examined in this study (rs4353135, rs6672995) decrease gene expression, and have been shown to be associated with Crohn's disease, while the gain of function NLRP3 (rs35829419, p.Q705K) variant has been associated with multiple disease phenotypes in adults ([@R11],[@R13],[@R23],[@R40]). CARD8 is known to inhibit Caspase-1 activation and NLRP3-dependent IL-1β activation ([@R41]). The CARD8 SNP (rs2043211, p.Cys10X) results in a truncated protein, and has been variably associated with IBD susceptibility ([@R14],[@R25]). We did not find an association between NLRP3 or CARD8 variants and NEC. Potential explanations for these negative results could be variation in expression or function of protein in the immature intestine, and preservation of function in the heterozygous state. Given the importance of NOD1, NOD2, and NLRP3 in sensing multiple stress and bacterial signatures, future studies are needed to further examine the role of these genes in NEC.

Previous studies examining the genetic basis of NEC vulnerability have predominantly focused on cytokine and TLR pathway genetic variants ([@R4],[@R5],[@R24],[@R39]). Except for Hartel et al. ([@R24]) these studies have been generally limited by a small sample size and lack of replication. In this multi-center study we investigated the relationship between candidate NLR and autophagy SNPs and NEC in a preterm cohort. To the best of our knowledge, this is the first study to examine the relationship between ATG16L1 variants and NEC. We found that a hypomorphic ATG16L1 variant (rs2241880) was less prevalent in infants who developed NEC while functional variants in NOD1, NOD2, and NLRP3 were not associated with NEC. The lack of replication in a smaller cohort, in spite of a similar observable trend limits labeling the ATG16L1 variant as a validated genetic marker. Our results suggest that decreased autophagy resulting from loss of function variants in autophagy genes may protect against NEC. The mechanisms by which ATG16L1 and autophagy regulate host-microbiome interactions in the preterm intestine, and functional implications of the variant examined on these interactions are topics for broader research.

METHODS {#S13}
=======

Recruitment of study subjects {#S14}
-----------------------------

Premature infants were recruited from neonatal intensive care units at Children's Hospital of Wisconsin (Milwaukee, WI), St. Joseph's Hospital (Milwaukee, WI), Kosair's Children's Hospital (Louisville, KY), Children's Hospitals and Clinics of Minnesota (Minneapolis, MN), and the University of Alabama at Birmingham (Birmingham, AL) after institutional review board (IRB) approval at respective centers. After informed consent, 0.5 mL of blood was collected in coded sample containers, and shipped to Children's Hospital of Wisconsin where DNA extraction and genotyping was done. Clinical and epidemiological data from infants recruited at these centers were de-identified and assigned a study code linked to their de-identified blood samples. Additional premature infant DNA samples were obtained from subjects recruited through IRB-approved studies at University of Iowa Children's Hospital (Iowa City, IA) and BC Children's & Women's Health Centre (Vancouver, Canada). Sample recruited through a collaborative effort at Yale-New Haven Children's Hospital (New Haven, CT), as part of the Neonatal Genetics Group (listed in the acknowledgment section) were used for a replication cohort. The study was approved by the Human Investigation Committee at Yale University as well as the respective Institutional Review Boards at the collaborating institutions. For infants from these sites, de-identified DNA samples and clinical data were used for studies and analysis.

Eligibility criteria {#S15}
--------------------

Infants born with a gestational age ≤ 35 weeks admitted to the participating centers were eligible. Infants with major congenital anomalies of the heart, gastro-intestinal tract, renal or respiratory tract were excluded. ***Case definition:*** NEC was defined as per modified Bell's criteria ([@R42]). Infants with stage I NEC were analyzed as cases. Infants who had surgery for NEC were also identified. Spontaneous ileal perforation was distinguished from NEC based on age of diagnosis, feeding history, and surgical data. These infants were excluded as NEC cases.

Selection of SNPs {#S16}
-----------------

Candidate NLR SNPs were identified based on whether: i) associations with inflammatory bowel disease or Crohn's disease have been reported, ii) variants had a functional effect, and iii) variants had a mean allele frequency (MAF) \> 2% in the Caucasian population.

Laboratory procedure {#S17}
--------------------

Genomic DNA was extracted from blood samples using the FlexiGene DNA kit (Qiagen, Inc., Valencia, CA) and stored at 4°C. To genotype the NOD1 (rs6958571), NOD2 (rs2066844), ATG16L1 (rs2241880), CARD8 (rs2043211), and NLRP3 (rs4353135, rs6672995, and rs35829419) variants we performed a 5′ nuclease Taqman assay (Applied Biosystems, Foster City, CA) using custom or predesigned TaqMan SNP Genotyping Assay probes (ABI, Foster City, CA) as per the manufacturer's instructions ([@R43]). The principle of the assay involves amplification of the genomic region of interest followed with ligation with allele-specific probes that emit a distinct fluorescent signal specific to the variant or reference allele. Samples were analyzed on ABI HT7900 with SDS 2.3 software package (probes available on request). Genotyping was done by personnel blinded to clinical outcomes. ***Quality control:*** 10% of the samples were re-genotyped by an independent technician blinded to prior results. There was \>99% concordance for all samples.

Statistical analysis {#S18}
--------------------

Chi-square analyses were used for comparisons between dichotomous clinical variables and NEC outcomes. Gestational age (GA) and birth-weight were compared between groups using the Wilcoxon-Mann-Whitney rank sum test. Associations between genetic variants and GA were examined using the Kruskal-Wallis test. We used an additive genetic risk model to analyze relationships between SNPs and NEC outcomes. Variant allele frequencies were compared among infants with and without NEC using the Pearson's Chi-square test or Fisher's exact test. The Cochran-Armitage trend test was used to examine the additive risk associated with risk alleles. In pre-specified a priori analysis, relationships between SNPs and NEC would be examined in Caucasian (CAU) and African American (AA) infants independently. We also examined the association between NLR variants and surgical NEC in our cohort. **Power:** Assuming a NEC incidence of 8% in our primary cohort, we estimated that a sample size of \~ 950 infants would give us 80% power with a p=0.05 to detect a 10-- 20 % difference in the prevalence of the variant allele between infants with and without NEC. To control for potential epidemiological confounders, we analyzed data using logistic regression with backward elimination where the probability of removal was set at p≥0.05. In this model, birth variables (GA, birth-weight, clinical chorioamnionitis, antenatal steroid exposure, race, sex) along with NLR SNPs were examined for association with NEC. Variables were removed from the model in a stepwise fashion till only those associated with NEC (p\<0.05) remained. Risk factors for severe NEC were modeled in a similar fashion. The Hosmer and Lemeshow Goodness-of-Fit test was used to assess the degree of fit in regression models. SPSS 21.0 (SPSS Inc., Chicago, IL) and SAS 9.2 (SAS Inc., NC) were used for data analysis.
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![ATG16L1 variant genotypes and NEC in the (a) primary and (b) replication cohorts\
The proportion of infants who developed NEC stratified by their ATG16L1 (rs2241880) genotypes is shown. The N for NEC infants/all infants within each genotype are as follows: AA- 36/320; AG- 40/478; GG- 10/209. Cochran-Armitage tests were used to evaluate risk associated with the SNP. (a) \* - p=0.009 (AA vs. AG vs. GG genotypes; Cochran-Armitage trend test). (b) p=0.30 (AA vs. AG vs. GG genotypes; Cochran-Armitage trend test).](nihms832131f1){#F1}

![ATG16L1 variant genotypes and NEC outcomes stratified by race in the combined cohort\
NEC outcomes among Caucasian (white bars) and African American (grey bars) infants stratified by ATG16L1 (rs2241880) genotypes is shown. The N for NEC infants/all infants among Caucasian and African American infants were respectively: AA - 27/233; AG -33/427; GG - 11/216, and AA - 19/125; AG - 11/121; GG - 2/35. Cochran-Armitage tests were used to evaluate risk associated with the SNP. \* - p=0.01 (NEC in Caucasians with AA vs. AG vs. GG genotypes): \*\* - p=0.07 (NEC in African Americans with AA vs. AG vs. GG genotypes).](nihms832131f2){#F2}

###### 

Distribution of clinical/epidemiological variables in our NEC cohort

  -----------------------------------------------------------------------------------------------------------
  Clinical variable                                      Infants without NEC\   Infants with NEC\   P value
                                                         (n= 929)               (n=86)              
  ------------------------------------------------------ ---------------------- ------------------- ---------
  Gestational age (wk)                                   28 (26, 29)            26 (25, 29)         0.006

  Birth weight (BW; gram)                                1010 (790, 1263)       890 (699, 1290)     0.13

  Infants with GA\<29wk                                  579 (62.4%)            61 (70.9%)          NS

  Infants with BW \<1000g                                444 (48.8%)            50 (58.1%)          0.067

  Antenatal steroid use                                  781 (84.6%)            70 (81.3%)          NS

  Race Caucasian                                         659 (71%)              57 (66.3%)          NS

  African American                                       174 (18.7%)            23 (26.7%)          

  Other                                                  96 (10.3)              6 (7.0%)            

  Male gender                                            479 (51.6%)            47 (54.6%)          NS

  Clinical\                                              80 (8.6%)              10 (11.6%)          NS
  Chorioamnionitis                                                                                  

  Type of feeding [a](#TFN2){ref-type="table-fn"}                                                   NS

  Breast milk                                            322 (55.5%)            22 (44%)            

  Formula milk                                           106 (18.3%)            12 (24%)            

  Both                                                   152 (26.2%)            16 (32%)            

  Medically-treated PDA[b](#TFN3){ref-type="table-fn"}   293/794 (37%)          29/72 (40.3%)       NS
  -----------------------------------------------------------------------------------------------------------

Data is represented as Median (25^th^, 75^th^ centile) or as raw numbers (n) with percentages (%). For comparisons between birth weight and gestational age the Mann-Whitney U test was used. Chi-square tests were used for all other comparisons.

Feeding information was not available in 385 infants of the 1015 infants.

Data unavailable for 149 infants.

###### 

Distribution of NLR pathway genetic variants in our primary cohort

  Variant                Genotype Frequency -- Number (%)                         
  ---------------------- ------------------------------------------- ------------ ------------------------------------------
  ATG16L1 rs2241880 AA   284 (30.8)[a](#TFN5){ref-type="table-fn"}   36 (41.9)    11 (42.3%)
   AG                    438 (47.6)                                  40 (46. 5)   12 (46.2%)
   GG                    199 (21.6)                                  10 (11.6)    3 (1.5%)
  CARD8 rs2043211 AA     445 (48)                                    47 (54.7)    16 (61.5%)
   AT                    397 (42.9)                                  31 (36)      7 (26.9%)
   TT                    84 (9.1)                                    8 (9.3)      3 (11.6%)
  NLRP3 rs4353135 TT     459 (49.7)                                  44 (51.2)    12 (46.2)
   GT                    379 (41.1)                                  33 (38.4)    10 (38.5%)
                         85 (9.2)                                    9 (10.4)     4 (15.3%)
  NLRP3 rs6672995 GG     674 (72.6)                                  60 (69.8)    18 (69.2%)
   AG                    231 (24.9)                                  23 (26.7)    6 (23.1%)
   AA                    23 (2.5)                                    3 (3.5)      2 (7.7%)
  NLRP3 rs35829419 CC    864 (93.2)                                  82 (95.3)    25 (96.2%)
   AC                    63 (6.8)                                    3 (3.5)      1 (3.8%)
   AA                    1 (\<0.1)                                   1 (1.2)      0
  NOD1 rs6958571 AA      506 (54.8)                                  46 (53.5)    20 (77%) [b](#TFN6){ref-type="table-fn"}
   AC                    340 (36.8)                                  36 (41.9)    5 (19.2%)
   CC                    77 (8.4)                                    4 (4.6)      1 (3.8%)
  NOD2 rs2066844 CC      871 (94.2)                                  80 (93)      24 (92.4%)
   CT                    54 (5.8)                                    6 (7)        2 (7.6%)
   TT                    1 (\<0.1)                                   0            0

Genotype frequencies of individual variants among infants with and without NEC are presented. rs number; reference SNP accession ID number. Genotyping results were unavailable for the following variants in our primary cohort; CARD8 and NOD2 (n=2 each), ATG16L1 (n=8), and NLRP3 rs4353135 and NOD1 (n=6 each). Among infants with NEC, data on surgical NEC was unavailable in 7 infants. Cochran Armitage trend test was used to determine associations between variants and NEC.

p=0.009,

p=0.042
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